Matthew Porteus, MD
Professor of Pediatrics, Stanford University
Matthew Porteus MD, PhD is the Sutardja Chuk Professor of Definitive and Curative Medicine and a Professor in the Department of Pediatrics, Institute of Stem Cell Biology and Regenerative Medicine and Maternal-Child Health Research Institute at Stanford. He is the Director of the Stanford Center for Definitive and Curative Medicine and the co-Executive Director of the Stanford Cell and Gene Therapy GMP Facility called the Laboratory for Cell and Gene Medicine. His primary research focus is on developing genome editing as an approach to cure disease, particularly those of the blood (most notably sickle cell disease) but also of other organ systems as well. He received his undergraduate degree at Harvard in History and Science where his honors thesis studied the recombinant DNA controversy of the 1970s. He then completed his MD and PhD training at Stanford, clinical training in Pediatric Hematology/Oncology at Boston Children’s Hospital, and post-doctoral research training with Noble Laureate David Baltimore at CalTech. He works as an attending physician on the Pediatric Hematopoietic Stem Cell Transplant service at Lucile Packard Children’s Hospital where he cares for children under going bone marrow transplantation for both malignant and non-malignant diseases. His goal is to combine his research and clinical interests to develop innovative curative therapies. He served on the 2017 National Academy Study Committee of Human Genome Editing and currently serves on the Scientific Advisory Board for WADA on Cell and Gene Doping and the NIH NexTRAC advisory committee evaluating the emergence of new technologies. He has been a scientific founder of CRISPR Tx and a founder of Graphite Bio and serves on several SAB’s. He is a strong advocate for assuring that the next generation of transformative medicines reaches the global community in partnership with those communities
Got a Question for Matthew Porteus, MD?
Get in touch using the contact form linked here and we’ll get back to you shortly.